Allostery Investments LP Purchases Shares of 431,117 Evolus, Inc. (NASDAQ:EOLS)

Allostery Investments LP purchased a new stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 431,117 shares of the company's stock, valued at approximately $4,760,000. Evolus comprises about 4.9% of Allostery Investments LP's investment portfolio, making the stock its 3rd biggest holding. Allostery Investments LP owned approximately 0.68% of Evolus as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. KBC Group NV bought a new stake in shares of Evolus during the 4th quarter valued at $49,000. IFP Advisors Inc raised its position in shares of Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after purchasing an additional 4,709 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Evolus during the 4th quarter valued at $106,000. Quantbot Technologies LP bought a new position in Evolus in the 4th quarter worth $118,000. Finally, Freestone Grove Partners LP bought a new stake in Evolus during the fourth quarter valued at about $140,000. Hedge funds and other institutional investors own 90.69% of the company's stock.

Evolus Price Performance

Shares of NASDAQ:EOLS traded up $0.51 on Wednesday, reaching $12.12. The company's stock had a trading volume of 419,236 shares, compared to its average volume of 667,815. The company has a 50-day simple moving average of $11.89 and a 200 day simple moving average of $12.67. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The company has a market cap of $781.45 million, a P/E ratio of -13.34 and a beta of 1.11. Evolus, Inc. has a 52-week low of $8.67 and a 52-week high of $17.82.

Insiders Place Their Bets

In related news, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the business's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $60,147.36. Following the completion of the transaction, the chief marketing officer now owns 95,671 shares in the company, valued at $1,268,597.46. The trade was a 4.53 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Sandra Beaver sold 8,996 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $119,286.96. Following the completion of the transaction, the chief financial officer now directly owns 173,583 shares in the company, valued at approximately $2,301,710.58. This trade represents a 4.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 60,575 shares of company stock valued at $794,369 over the last ninety days. 6.10% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts recently issued reports on EOLS shares. BTIG Research assumed coverage on Evolus in a research report on Thursday, April 17th. They set a "buy" rating and a $21.00 target price for the company. HC Wainwright reiterated a "buy" rating and set a $27.00 price objective on shares of Evolus in a research report on Thursday, April 10th. Barclays upped their target price on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price target on shares of Evolus in a research note on Wednesday, April 9th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $23.75.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.